These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 37037489)

  • 1. Everolimus in combination with octreotide LAR in thymic atypical carcinoid.
    Sakane T; Nakano T; Hagui E; Haneda H; Okuda K
    Thorac Cancer; 2023 May; 14(15):1404-1407. PubMed ID: 37037489
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Two cases of thymic carcinoid treated with octreotide long-acting repeatable].
    Okabe N; Inoue T; Watanabe Y; Muto S; Hasegawa T; Ohsugi J; Higuchi M; Shio Y; Suzuki H
    Gan To Kagaku Ryoho; 2014 Jul; 41(7):879-83. PubMed ID: 25131876
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy and safety of long-acting pasireotide or everolimus alone or in combination in patients with advanced carcinoids of the lung and thymus (LUNA): an open-label, multicentre, randomised, phase 2 trial.
    Ferolla P; Brizzi MP; Meyer T; Mansoor W; Mazieres J; Do Cao C; Léna H; Berruti A; Damiano V; Buikhuisen W; Grønbæk H; Lombard-Bohas C; Grohé C; Minotti V; Tiseo M; De Castro J; Reed N; Gislimberti G; Singh N; Stankovic M; Öberg K; Baudin E
    Lancet Oncol; 2017 Dec; 18(12):1652-1664. PubMed ID: 29074099
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [A Case of Primary Thymic Carcinoid Treated with Everolimus and Octreotide].
    Katagiri Y; Yanagawa N; Shiono S; Yuki Y; Muramatsu S; Hino T; Suzuki H
    Gan To Kagaku Ryoho; 2019 Sep; 46(9):1445-1447. PubMed ID: 31530787
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study.
    Pavel ME; Hainsworth JD; Baudin E; Peeters M; Hörsch D; Winkler RE; Klimovsky J; Lebwohl D; Jehl V; Wolin EM; Öberg K; Van Cutsem E; Yao JC;
    Lancet; 2011 Dec; 378(9808):2005-2012. PubMed ID: 22119496
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metastatic thymic carcinoid responds to chemoradiation and octreotide: A case report.
    Mei Z; Wang H; Ren S; Wei J; Gu Y
    Medicine (Baltimore); 2018 Nov; 97(47):e13286. PubMed ID: 30461637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incidental metastatic mediastinal atypical carcinoid in a patient with parathyroid adenoma: a case report.
    Kiran Z; Ahmed A; Rashid O; Fatima S; Malik F; Fatimi S; Ikram M
    J Med Case Rep; 2017 Mar; 11(1):81. PubMed ID: 28342443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thymic carcinoid responds to neoadjuvant therapy with sunitinib and octreotide: a case report.
    Dham A; Truskinovsky AM; Dudek AZ
    J Thorac Oncol; 2008 Jan; 3(1):94-7. PubMed ID: 18166847
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [A case of rectal carcinoid with multiple liver, lymph nodes and bone metastases that responded to an octreotide therapy].
    Yamashita K; Takase S; Nakamura T; Matsuda Y; Imanishi T; Sumi Y; Suzuki S; Kamigaki T; Ku Y; Kuroda D
    Gan To Kagaku Ryoho; 2010 Nov; 37(12):2349-51. PubMed ID: 21224569
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Thymic carcinoid with lymph node metastases; report of a case].
    Nakamura Y; Sato N; Kaimori K; Imai T
    Kyobu Geka; 2007 Dec; 60(13):1204-7. PubMed ID: 18078092
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Capecitabine and Temozolomide as a Promising Therapy for Advanced Thymic Atypical Carcinoid.
    Wang X; Li Y; Duan J; Chen Y; Yuan B; Qi Z; Tan H
    Oncologist; 2019 Jun; 24(6):798-802. PubMed ID: 30413666
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of Previous Somatostatin Analogue Use on the Activity of Everolimus in Patients with Advanced Neuroendocrine Tumors: Analysis from the Phase III RADIANT-2 Trial.
    Anthony LB; Pavel ME; Hainsworth JD; Kvols LK; Segal S; Hörsch D; Van Cutsem E; Öberg K; Yao JC
    Neuroendocrinology; 2015; 102(1-2):18-25. PubMed ID: 25824001
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study.
    Yao JC; Phan AT; Chang DZ; Wolff RA; Hess K; Gupta S; Jacobs C; Mares JE; Landgraf AN; Rashid A; Meric-Bernstam F
    J Clin Oncol; 2008 Sep; 26(26):4311-8. PubMed ID: 18779618
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of everolimus plus octreotide LAR in patients with advanced neuroendocrine tumor and carcinoid syndrome: final overall survival from the randomized, placebo-controlled phase 3 RADIANT-2 study.
    Pavel ME; Baudin E; Öberg KE; Hainsworth JD; Voi M; Rouyrre N; Peeters M; Gross DJ; Yao JC
    Ann Oncol; 2017 Jul; 28(7):1569-1575. PubMed ID: 28444114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lung and Thymic Carcinoids.
    Hann CL; Forde PM
    Endocrinol Metab Clin North Am; 2018 Sep; 47(3):699-709. PubMed ID: 30098725
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase III study of pasireotide long-acting release in patients with metastatic neuroendocrine tumors and carcinoid symptoms refractory to available somatostatin analogues.
    Wolin EM; Jarzab B; Eriksson B; Walter T; Toumpanakis C; Morse MA; Tomassetti P; Weber MM; Fogelman DR; Ramage J; Poon D; Gadbaw B; Li J; Pasieka JL; Mahamat A; Swahn F; Newell-Price J; Mansoor W; Öberg K
    Drug Des Devel Ther; 2015; 9():5075-86. PubMed ID: 26366058
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Multimodal therapy improved carcinoid syndrome secondary to liver metastases of an atypical lung carcinoid tumor:a case report].
    Shimizu T; Adikrisna R; Shimada K; Uchidate K; Fukuda K; Oyama A; Ueda M; Goto F; Suzuki M; Kawamura T
    Nihon Shokakibyo Gakkai Zasshi; 2020; 117(7):635-645. PubMed ID: 32655123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Everolimus plus octreotide long-acting repeatable in patients with advanced lung neuroendocrine tumors: analysis of the phase 3, randomized, placebo-controlled RADIANT-2 study.
    Fazio N; Granberg D; Grossman A; Saletan S; Klimovsky J; Panneerselvam A; Wolin EM
    Chest; 2013 Apr; 143(4):955-962. PubMed ID: 23187897
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ectopic ACTH syndrome due to thymic atypical carcinoid treated with combination chemotherapy of cisplatin and etoposide.
    Takahashi T; Hatao K; Yamashita Y; Tanizawa Y
    Intern Med; 2003 Dec; 42(12):1197-201. PubMed ID: 14714958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical outcomes of atypical carcinoid tumors of the lung and thymus: 7-year experience of a rare malignancy at single institute.
    Han B; Sun JM; Ahn JS; Park K; Ahn MJ
    Med Oncol; 2013 Mar; 30(1):479. PubMed ID: 23377986
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.